TEVA-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Ph+ CML in chronic, accelerated or blast phase or after failure of interferon therapy.
TEVA-IMATINIB is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
TEVA-IMATINIB is also indicated for the treatment of adult patients with relapsed or refractory Ph+ ALL as single agent.
TEVA-IMATINIB is also indicated for the treatment of adult patients with myelodysplastic/Myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
TEVA-IMATINIB is also indicated for the treatment of adult patients with aggressive sub-types of systemic mastocytosis (ASM and SM-AHNMD1) without the D816V c-Kit mutation. Ifc-Kit mutational status in patients with ASM or SM-AHNMD1 is not known or unavailable, treatment with TEVA-IMATINIB may be considered if there is no satisfactory response to other therapies.
TEVA-IMATINIB is also indicated for the treatment of adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRα rearrangement.
TEVA-IMATINIB is also indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)
